Catalent Expands Biologics Business With Acquisition Of Cook Pharmica
The acquisition strengthens Catalent’s position as a leader in the rapidly growing area of biologics development and analytical services, manufacturing and finished product supply.
Catalent finalizes the acquisition of Cook Pharmica, Positioning Catalent Biologics as a Leading Partner from Development to Commercialization
Catalent Biologics has acquired Bloomington, Indiana-based Cook Pharmica. By bringing together complimentary capabilities, the combined organization provide biotech developers a Single Partner from cell line development through commercial supply of biologics in liquid and lyophilized vials, prefilled syringes and cartridges.
“The complementary biologics development, biomanufacturing, and fill-finish capabilities of Catalent and Cook Pharmica will provide biopharmaceutical firms with a single, integrated partner supporting a wide range of clinical and commercial needs,” said John Chiminski, Chair and CEO of Catalent.
The acquisition strengthens the Catalent Biologics global network which will now include, the Cook Pharmica integrated drug substance, drug product facility, a state-of-the-art biologics development and biomanufacturing facility in Madison, Wisconsin; fill/finish services in Brussels, Belgium and Limoges, France; SMARTag® conjugation technology in Emeryville, California; and a network of biologics analytical locations.
Cook Pharmica’s Bloomington facility has extensive bio-manufacturing capacity and deep expertise in sterile formulation and fill/finish across liquid and lyophilized vials, pre-filled syringes, and cartridges. It perfectly augments Catalent’s expertise in cell line engineering, bioconjugate development, analytical services, bio-manufacturing, prefilled syringe, and blow/fill/seal technologies.
In combination with Cook Pharmica, Catalent Biologics now offers a comprehensive portfolio of integrated solutions to help biotech developers deliver better treatments to patients, faster.
- Cell Line Engineering – GPEx® Technology
- ADC & Bioconjugates –SMARTag® Technology
- Biomanufacturing – Clinical & Commercial
- Biologics Analytical Services –Integrated and Stand-Alone
- Fill/Finish - Cook Pharmica’s drug product business brings 3 lines in Indiana that can produce up to 100M units annually, complementing Catalent’s existing 175M unit capacity across its pre-filled syringe and auto-injector lines in Brussels, Belgium.
- Clinical Supply Services & Solutions for Biologics
Contact Us about how we can help solve your most complex Biologic challenge.